The endocrinologist or prescribing physician manages the indication for treatment, dose escalation, metabolic response, systemic side effects and long-term safety
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
The 7 key differences between Tresiba and GLP-1 medications The confusion between Tresiba and GLP-1 medications usually stems from surface-level similarities
Yersinia pestis LcrV, the cap protein of T3SS, is glutathionylated at cysteine residue 273 (C273) [40]
Your dispensing pharmacy will include handling, dosing, and safety instructions specific to your prescription
